95 related articles for article (PubMed ID: 16029117)
41. Calcium/Calmodulin-dependent protein kinase II and its endogenous inhibitor α in medullary thyroid cancer.
Russo E; Salzano M; De Falco V; Mian C; Barollo S; Secondo A; Bifulco M; Vitale M
Clin Cancer Res; 2014 Mar; 20(6):1513-20. PubMed ID: 24449826
[TBL] [Abstract][Full Text] [Related]
42. Type 2 iodothyronine deiodinase is highly expressed in medullary thyroid carcinoma.
Meyer EL; Goemann IM; Dora JM; Wagner MS; Maia AL
Mol Cell Endocrinol; 2008 Jul; 289(1-2):16-22. PubMed ID: 18514391
[TBL] [Abstract][Full Text] [Related]
43. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
[TBL] [Abstract][Full Text] [Related]
44. Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas.
Shida T; Furuya M; Nikaido T; Kishimoto T; Koda K; Oda K; Nakatani Y; Miyazaki M; Ishikura H
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):450-8. PubMed ID: 15701827
[TBL] [Abstract][Full Text] [Related]
45. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
46. RET signals through focal adhesion kinase in medullary thyroid cancer cells.
Panta GR; Nwariaku F; Kim LT
Surgery; 2004 Dec; 136(6):1212-7. PubMed ID: 15657578
[TBL] [Abstract][Full Text] [Related]
47. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
[TBL] [Abstract][Full Text] [Related]
48. Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.
Cook MR; Pinchot SN; Jaskula-Sztul R; Luo J; Kunnimalaiyaan M; Chen H
Mol Cancer Ther; 2010 Feb; 9(2):429-37. PubMed ID: 20103603
[TBL] [Abstract][Full Text] [Related]
49. Human achaete-scute homolog-1 is highly expressed in a subset of neuroendocrine tumors.
Chen H; Udelsman R; Zeiger M; Ball D
Oncol Rep; 1997; 4(4):775-8. PubMed ID: 21590138
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
[TBL] [Abstract][Full Text] [Related]
51. ASC proneural factors are necessary for chromatin remodeling during neuroectodermal to neuroblast fate transition to ensure the timely initiation of the neural stem cell program.
Theodorou V; Stefanaki A; Drakos M; Triantafyllou D; Delidakis C
BMC Biol; 2022 May; 20(1):107. PubMed ID: 35549704
[TBL] [Abstract][Full Text] [Related]
52. ASCL1 regulates neurodevelopmental transcription factors and cell cycle genes in brain tumors of glioma mouse models.
Vue TY; Kollipara RK; Borromeo MD; Smith T; Mashimo T; Burns DK; Bachoo RM; Johnson JE
Glia; 2020 Dec; 68(12):2613-2630. PubMed ID: 32573857
[TBL] [Abstract][Full Text] [Related]
53. Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction.
Jaskula-Sztul R; Eide J; Tesfazghi S; Dammalapati A; Harrison AD; Yu XM; Scheinebeck C; Winston-McPherson G; Kupcho KR; Robers MB; Hundal AK; Tang W; Chen H
Mol Cancer Ther; 2015 Feb; 14(2):499-512. PubMed ID: 25512616
[TBL] [Abstract][Full Text] [Related]
54. Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy.
Xu W; Burke JF; Pilla S; Chen H; Jaskula-Sztul R; Gong S
Nanoscale; 2013 Oct; 5(20):9924-33. PubMed ID: 23986296
[TBL] [Abstract][Full Text] [Related]
55. MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.
Burke JF; Schlosser L; Harrison AD; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2013 Nov; 20(12):3862-8. PubMed ID: 23900743
[TBL] [Abstract][Full Text] [Related]
56. Tumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells.
Kunnimalaiyaan M; Haymart MR; Chen H
Transl Oncogenomics; 2007; 2():43-7. PubMed ID: 23641144
[TBL] [Abstract][Full Text] [Related]
57. Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.
Somnay Y; Chen H; Kunnimalaiyaan M
Neuroendocrinology; 2013; 97(2):183-92. PubMed ID: 22965070
[TBL] [Abstract][Full Text] [Related]
58. A novel function of the proneural factor Ascl1 in progenitor proliferation identified by genome-wide characterization of its targets.
Castro DS; Martynoga B; Parras C; Ramesh V; Pacary E; Johnston C; Drechsel D; Lebel-Potter M; Garcia LG; Hunt C; Dolle D; Bithell A; Ettwiller L; Buckley N; Guillemot F
Genes Dev; 2011 May; 25(9):930-45. PubMed ID: 21536733
[TBL] [Abstract][Full Text] [Related]
59. Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.
Truong M; Cook MR; Pinchot SN; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2011 May; 18(5):1506-11. PubMed ID: 21184191
[TBL] [Abstract][Full Text] [Related]
60. Signaling mechanisms in neuroendocrine tumors as targets for therapy.
Zarebczan B; Chen H
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):801-10. PubMed ID: 21095546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
